Associated Papers
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_2_late_met_1
Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.
Rhoads K et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2011
Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC et al.
Pharmacogenetics and Genomics, 2010
Select a paper to view details